US2017369562A1PendingUtilityA1

Methods for treating complement-associated disorders

65
Assignee: ALEXION PHARMA INCPriority: Nov 10, 2008Filed: Sep 11, 2017Published: Dec 28, 2017
Est. expiryNov 10, 2028(~2.3 yrs left)· nominal 20-yr term from priority
Inventors:Russell P. RotherCamille BedrosianStephen P. SquintoLeonard Bell
A61P 7/04A61P 9/12A61P 37/02A61P 37/06A61P 7/02A61P 9/00A61P 43/00A61P 9/14A61P 21/04A61P 21/02A61P 13/12A61K 38/00A61K 39/395A61K 2039/545A61K 45/06C07K 16/18A61K 39/3955A61K 9/0019A61K 2039/505C07K 2317/34C07K 2317/24A61K 38/16A61K 2039/54A61K 38/19
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. In some embodiments, the inhibitor is administered to a patient in an amount and with a frequency to maintain systemic complement inhibition and prevent breakthrough. In some embodiments, the compositions contain an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or a fragment of the protein such as C5a or C5b.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for treating a patient having a complement-associated disorder comprising administering to the patient a safe and effective amount of a composition comprising eculizumab, wherein eculizumab is administered at a dose of 1000 mg or greater once every 12 to 14 days. 
     
     
         2 . The method of  claim 1 , wherein eculizumab is administered every 14 days. 
     
     
         3 . The method of  claim 1 , wherein the dose is 1050 mg or greater. 
     
     
         4 . The method of  claim 1 , wherein the dose is 1100 mg or greater. 
     
     
         5 . The method of  claim 1 , wherein the dose is 1150 mg or greater. 
     
     
         6 . The method of  claim 1 , wherein the dose is 1200 mg or greater. 
     
     
         7 . The method of  claim 1 , wherein the dose is 1250 mg or greater. 
     
     
         8 . The method of  claim 1 , wherein the dose is 1300 mg or greater. 
     
     
         9 . The method of  claim 1 , wherein the dose is 1350 mg or greater. 
     
     
         10 . The method of  claim 1 , wherein the dose is 1400 mg or greater. 
     
     
         11 . The method of  claim 1 , wherein eculizumab is administered for at least three months. 
     
     
         12 . The method of  claim 1 , wherein eculizumab is administered for at least six months. 
     
     
         13 . The method of  claim 1 , wherein eculizumab is administered for at least nine months. 
     
     
         14 . The method of  claim 1 , wherein eculizumab is administered for at least one year. 
     
     
         15 . The method of  claim 1 , wherein eculizumab is administered for two or more years.

Join the waitlist — get patent alerts

Track US2017369562A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.